Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion

Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion

Abstract Background Glioblastoma patients commonly develop resistance to temozolomide chemotherapy. Hypoxia, which supports chemotherapy resistance, favors the expansion of glioblastoma stem cells (GSC), contributing to tumor relapse. Because of a deregulated sphingolipid metabolism, glioblastoma ti...

Full description

Bibliographic Details
Main Authors: Nadia Sousa, Carsten Geiß, Laura Bindila, Ingo Lieberwirth, Ella Kim, Anne Régnier-Vigouroux
Format: Article
Language:English
Published: BMC 2023-08-01
Series:BMC Cancer
Subjects:
Hypoxia
Glioblastoma therapy
Drug combination
Temozolomide
SKI-II
Sphingolipids
Online Access:https://doi.org/10.1186/s12885-023-11271-w

Similar Items

Similar Items